Trevena Inc Stock Price, News & Analysis

On April 20, 2022, Trevena announced favorable results from a study on its drug OLINVYK (oliceridine) in elderly and overweight individuals, indicating a significantly reduced impact on respiratory function compared to IV morphine. Conducted in collaboration with Leiden University Medical Center, the study demonstrated that both drugs provided comparable pain relief, but OLINVYK exhibited better respiratory safety. Results are consistent with earlier studies in younger subjects, suggesting OLINVYK's potential for safer use in at-risk populations.

Trevena, Inc. (Nasdaq: TRVN) announced a significant financing milestone, receiving the first $15 million tranche from R-Bridge Healthcare Fund as part of a royalty-based agreement. This deal includes further funding of $15 million upon the first commercial sale of OLINVYK® in China and an additional $10 million contingent on achieving specific milestones. Trevena retains all milestone payments from its partner, Jiangsu Nhwa Pharmaceutical, including a critical $3 million milestone tied to OLINVYK's approval in China by year-end 2023.

Trevena, Inc. (Nasdaq: TRVN) reported on its participation in recent medical meetings focusing on OLINVYK® (oliceridine) injection for acute pain management. The company attended the 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting and the American Burn Association Annual Meeting, where OLINVYK data was highlighted, including a President's Choice abstract presentation on its low incidence of opioid-induced respiratory depression. OLINVYK, approved by the FDA in August 2020, is indicated for adults needing intravenous opioid analgesics.

Trevena, Inc. (Nasdaq: TRVN) announced a royalty-based financing deal with R-Bridge Healthcare Fund, securing an initial $15 million, with an additional $15 million contingent on OLINVYK's first commercial sale in China. The deal includes a 4% net revenue interest in U.S. sales of OLINVYK, capped at $10 million if Chinese approval is received by year-end 2023. Trevena retains its milestones from its partnership with Jiangsu Nhwa Pharmaceutical, including a $3 million milestone upon Chinese approval of OLINVYK. The financing is expected to enhance Trevena's financial position.

Trevena, Inc. (TRVN) reported its financial results for Q4 and full year 2021, revealing a year-end cash balance of $66.9 million, enough to fund operations through Q4 2022. The company highlighted the commercial launch of OLINVYK, with significant engagement with over 700 accounts. Patricia Drake was appointed as Chief Commercial Officer, bringing extensive experience. Positive topline data from an OLINVYK study indicated a statistically significant reduction in respiratory depression compared to IV morphine. A $40 million financing deal was secured for OLINVYK royalties from Jiangsu Nhwa in China.

Trevena, Inc. (Nasdaq: TRVN) announced that it will release its financial results for Q4 and full year 2021 on March 31, 2022, before market opening. The conference call is scheduled for the same day at 8:00 a.m. ET, featuring remarks from top executives including the CEO and CFO. Trevena has one approved product, OLINVYK, and a pipeline that includes four investigational drug candidates targeting various CNS disorders. A live webcast will accompany the call and will be accessible on the company’s website.

CHESTERBROOK, Pa., Feb. 3, 2022 (GLOBE NEWSWIRE) -- Trevena (Nasdaq: TRVN) will present a corporate overview at the BIO CEO & Investor Conference from February 14-17, 2022. Carrie Bourdow, President & CEO, leads the presentation, which includes a pre-recorded overview and one-on-one virtual meetings. The presentation will be available on-demand starting February 11, 2022. Trevena's pipeline includes innovative treatments for CNS disorders, such as OLINVYK for acute pain and investigational candidates like TRV250 for migraines and TRV734 for opioid use disorder.

Trevena, Inc. (Nasdaq: TRVN) announced that China’s National Medical Products Administration has accepted the New Drug Application (NDA) for OLINVYK (oliceridine injection), submitted by its partner Jiangsu Nhwa Pharmaceutical. This follows a Phase 3 bridging trial demonstrating the safety and efficacy of OLINVYK compared to IV morphine in Chinese patients. Trevena is eligible for future milestone payments and a 10% royalty on net sales in China upon approval and commercialization.

Trevena, Inc. (Nasdaq: TRVN) has announced the participation of CEO Carrie Bourdow and CFO Barry Shin in three virtual investor conferences this January. The conferences include the LifeSci Partners Annual Corporate Access Event from January 5-7, where a panel discussion on biopharmaceutical commercial launches will take place on January 5 at 7:30 AM ET. The company will also participate in the H.C. Wainwright BioConnect Virtual Conference from January 10-12 and BIO Partnering at JPM from January 10-13. Trevena focuses on CNS disorders and has one approved product, OLINVYK®.